ukmla MCQ (SBA): Type 2 diabetes therapy

Instant feedback + full explanation. One question, done properly.

MediumEndocrinologyType 2 diabetes therapyukmlamrcgp aktpanemrcp part 1prescribing safety assessment

A 64-year-old man with T2DM (HbA1c 67 mmol/mol) and BMI 33 kg/m² is on metformin maximum tolerated dose. eGFR 72. No ASCVD. What is the most appropriate second-line agent prioritising weight loss and cardiovascular risk reduction?

Educational content. Not a substitute for clinical judgement or local policy.

ukmla MCQ: Type 2 diabetes therapy — Answer & Explanation | iatroX